Drugs / HuL001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04540770 | Aug 2021 → Mar 2022 | idiopathic pulmonary fibrosis | HuniLife Biotechnology, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07210047 Comparator | Aug 2025 → Nov 2027 expected | plasma cell myeloma | HuniLife Biotechnology, Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HuL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04540770 ↗ |
| Modality | Monoclonal antibody | “Anti-ENO1 monoclonal antibody” NCT04540770 ↗ |
| Target | ENO1 | “Anti-ENO1 monoclonal antibody” NCT04540770 ↗ |